Antidiabetic activity of lipophilic (-)-epigallocatechin-3-gallate derivative under its role of α-glucosidase inhibition

Biomedicine and Pharmacotherapy

Volumn 61, Issue 1, 2007, Pages 91-96

  Li, Ting ^a   Liu, Jianwen ^a   Zhang, Xiaodong ^a   Ji, Guang ^b  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Glucosidase inhibitor; Blood glucose; Postprandial hyperglycemia

Indexed keywords

ALPHA GLUCOSIDASE; ANTIDIABETIC AGENT; CHOLESTEROL; EPIGALLOCATECHIN GALLATE; GLUCOSE; LIPID; LOW DENSITY LIPOPROTEIN; SUCROSE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIA; LIPOPHILICITY; MALE; METABOLITE; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

ALPHA-GLUCOSIDASES; ANIMALS; ANTIOXIDANTS; BODY WEIGHT; CATECHIN; DIABETES MELLITUS, EXPERIMENTAL; ENZYME INHIBITORS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33846621488     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2006.11.002     Document Type: Article

References (28)

1. Chehade J.M., and Mooradian A.D. A rational approach to drug therapy of type 2 diabetes mellitus. Drugs 60 (2000) 95-113
2. Van de Laar F.A., Lucassen P.L., Akkermans R.P., Van de Lisdonk E.H., Rutten G.E., and Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev (2005) CD003639
3. Scheen A.J. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus. Drugs 63 (2003) 933-951
4. Charpentier G. Oral combination therapy for type 2 diabetes. Diabetes Metab Res Rev 18 (2002) S70-S76
5. Shim Y.J., Doo H.K., Ahn S.Y., Kim Y.S., Seong J.K., Park I.S., and Min B.H. Inhibitory effect of aqueous extract from the gall of Rhus chinensis on alpha-glucosidase activity and postprandial blood glucose. J Ethnopharmacol 85 (2003) 283-287
6. Ye F., Shen Z., and Xie M. Alpha-glucosidase inhibition from a Chinese medical herb (Ramulus mori) in normal and diabetic rats and mice. Phytomedicine 9 (2002) 161-166
7. Gomes A., Vedasiromoni J.R., Das M., Sharma R.M., and Ganguly D.K. Anti-hyperglycemic effect of black tea (Camellia sinensis) in rat. J Ethnopharmacol 45 (1995) 223-226
8. Shukla Y., and Taneja P. Anticarcinogenic effect of black tea on pulmonary tumors in Swiss albino mice. Cancer Lett 176 (2002) 137-141
9. Skrzydlewska E., Ostrowska J., Farbiszewski R., and Michalak K. Protective effect of green tea against lipid peroxidation in the rat liver, blood serum and the brain. Phytomedicine 9 (2002) 232-238
10. Guo Q., Zhao B., Li M., Shen S., and Xin W. Studies on protective mechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes. Biochim Biophys Acta 1304 (1996) 210-222
11. Qanungo S., Das M., Haldar S., and Basu A. Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells. Carcinogenesis 26 (2005) 958-967
12. Choi Y.B., Kim Y.I., Lee K.S., Kim B.S., and Kim D.J. Protective effect of epigallocatechin gallate on brain damage after transient middle cerebral artery occlusion in rats. Brain Res 1019 (2004) 47-54
13. Raederstorff D.G., Schlachter M.F., Elste V., and Weber P. Effect of EGCG on lipid absorption and plasma lipid levels in rats. J Nutr Biochem 14 (2003) 326-332
14. Song E.K., Hur H., and Han M.K. Epigallocatechin gallate prevents autoimmune diabetes induced by multiple low doses of streptozotocin in mice. Arch Pharm Res 26 (2003) 559-563
15. Kao Y.H., Hiipakka R.A., and Liao S. Modulation of endocrine systems and food intake by green tea epigallocatechin gallate. Endocrinology 141 (2000) 980-987
16. Hong J., Lu H., Meng X., Ryu J.H., Hara Y., and Yang C.S. Stability, cellular uptake, biotransformation, and efflux of tea polyphenol (-)-epigallocatechin-3-gallate in HT-29 human colon adenocarcinoma cells. Cancer Res 62 (2002) 7241-7246
17. Chow H.H., Hakim I.A., Vining D.R., Crowell J.A., Ranger-Moore J., Chew W.M., et al. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res 11 (2005) 4627-4633
18. Wehbi G.J., Zimpelmann J., Carey R.M., Levine D.Z., and Burns K.D. Early streptozotocin-diabetes mellitus downregulates rat kidney AT2 receptors. Am. J Physiol Renal Physiol 280 (2001) F254-F265
19. Masuyama T., Fuse M., Yokoi N., Shinohara M., Tsujii H., Kanazawa M., et al. Genetic analysis for diabetes in a new rat model of nonobese type 2 diabetes. Biochem Biophys Res Commun 304 (2003) 196-206
20. Gaxiola G., Cuzon G., Garcia T., Taboada G., Brito R., Chimal M.E., et al. Factorial effects of salinity, dietary carbohydrate and moult cycle on digestive carbohydrates and hexokinases in Litopenaeus vannamei. Comp Biochem Physiol 140 (2005) 29-39
21. Tsuneki H., Ishizuka M., Terasawa M., Wu J.B., Sasaoka T., and Kimura I. Effect of green tea on blood glucose levels and serum proteomic patterns in diabetic (db/db) mice and on glucose metabolism in healthy humans. BMC Pharmacol 4 (2004) 18
22. Peter AL, Davidson MB, Schriger DL, Hasselblad V. A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. JAMA 2996;276:1246-52.
23. Sabu M.C., Smitha K., and Kuttan R. Anti-diabetic activity of green tea polyphenols and their role in reducing oxidative stress in experimental diabetes. J Ethnopharmacol 83 (2002) 109-116
24. Krentz A.J. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab 5 (2003) S19-S27
25. Brown B.G., Zhao X.Q., Sacco D.E., and Albers J.J. Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 87 (1993) 1781-1791
26. Han M.K. Epigallocatechin gallate, a constituent of green tea, suppresses cytokine-induced pancreatic beta-cell damage. Exp Mol Med 35 (2003) 136-139
27. Koyama Y., Abe K., Sano Y., Ishizaki Y., Njelekela M., Shoji Y., Hara Y., and Isemura M. Effects of green tea on gene expression of hepatic gluconeogenic enzymes in vivo. Planta Med 70 (2004) 1100-1102
28. Waltner-Law M.E., Wang X.L., Law B.K., Hall R.K., Nawano M., and Granner D.K. Epigallocatechin gallate, a constituent of green tea, represses hepatic glucose production. J Biol Chem 277 (2002) 34933-34940